You Are Here    Home   News

News
British HIV cure survey: most respondents would be prepared to take some health risk to help find a cure for HIV
by Gus Cairns, 2014-11-28 07:40
An online survey that asked people living with HIV, largely from the UK, whether they would participate in HIV cure research has found that the majority of participants would. Furthermore, they would be prepared to tolerate fairly significant risks to their health as long as they were explained clearly. The majority would also be

DAAs show good cure rates and liver function improvement for transplant recipients with recurrent HCV
by Liz Highleyman, 2014-11-27 07:40
Several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston focused on treating hepatitis C recurrence in liver transplant recipients, one of the most difficult populations to treat. Studies showed that a variety of interferon-free regimens containing the direct-acting antivirals sofosbuvir, simeprevir and daclatasvir led to

AbbVie 3D regimen cures recurrent HCV in most liver transplant recipients without cirrhosis
by Liz Highleyman, 2014-11-27 07:20
AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not yet developed advanced liver fibrosis or cirrhosis, according to results from the CORAL-I study presented at the American Association for the Study of Liver Diseases (AASLD) Liver

NHS urgently needs to make PrEP available, say HIV prevention organisations
by Roger Pebody, 2014-11-25 18:30
A group of community organisations working on HIV prevention have called for the NHS to speed up it processes and make pre-exposure prophylaxis (PrEP) available to those at the highest risk of acquiring HIV. The organisations point to the continued high rate of new infections and say there is an urgent need to improve

Tenofovir continues to suppress hepatitis B virus for eight years
by Liz Highleyman, 2014-11-25 08:30
Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting earlier this month in Boston, United States. Serological response rates continued to increase over time and kidney and bone-related side-effects remained

Tenofovir continues to suppresses hepatitis B virus for eight years
by Liz Highleyman, 2014-11-25 08:30
Most people with chronic hepatitis B who are treated with tenofovir for eight years continued to maintain viral suppression, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting earlier this month in Boston, United States. Serological response rates continued to increase over time and kidney and bone-related side-effects remained

Daclatasvir + sofosbuvir demonstrates good cure rate for genotype 3 hepatitis C
by Liz Highleyman, 2014-11-25 07:10
An all-oral combination of daclatasvir (Daklinza) plus sofosbuvir (Sovaldi), taken for 12 weeks, produced sustained virological response rates of 90% for previously untreated patients and 86% for prior non-responders with hepatitis C virus genotype 3 in the phase 3 ALLY-3 trial, researchers reported earlier this month at the American Association for the Study of

Positive response to 'gift tokens for undetectable viral load' trial
by Gus Cairns, 2014-11-24 08:50
A US study presented at last month’s HIV Research for Prevention conference found generally positive responses among people with HIV and clinic staff to a trial that used $70 gift tokens as an incentive for people to attend clinic regularly, refill their HIV treatment drug prescriptions, and maintain an undetectable viral load. However, the study found